MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cybin Inc.

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
From Cybin Inc.
Via Business Wire
Tickers CYBN DMTTF TSX-V:DMT
News headline image
Small Pharma Obtains Final Order Approving Arrangement
From Cybin Inc.
Via Business Wire
Tickers CYBN DMTTF TSX-V:DMT
News headline image
Cybin Announces Results of Annual and Special Meeting of Shareholders
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summit
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Participate in the Cantor Global Healthcare Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Date of Annual and Special Meeting of Shareholders
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Grant of U.S. Patent Covering Deuterated Tryptamines
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Acquire Small Pharma Inc.
From Cybin Inc.
Via Business Wire
Tickers CYBN DMTTF TSX-V:DMT
News headline image
Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Reports First Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Closing of Overnight Marketed Public Offering of Units
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Units
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Overnight Marketed Public Offering of Units
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Partners With Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Publication of Sponsored Feasibility Study Validating Kernel’s Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Participate in PSYCH Symposium London 2023
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer
From Cybin Inc.
Via Business Wire
Tickers CYBN
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story